Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

India Curbs Exports Amid Coronavirus

Restricted Products Include Paracetamol API And Formulations

Executive Summary

India has published a list of APIs and formulations for which exports will be restricted, with immediate effect. The move comes against the backdrop of growing concerns over the off-patent industry’s supply chain given the ongoing pressures caused by the coronavirus outbreak.

You may also be interested in...



‘Critical To Bring Back Domestic Manufacturing Of Key Essentials’ Insists Phlow CEO

In an exclusive interview with Generics Bulletin, Phlow Corp CEO Eric Edwards has criticized the growing list of drug shortages in the US. He outlined the government-backed company’s objective of tackling drug shortages and supply chain vulnerabilities, to create a national stockpile of essential medicines.

Indoco Sees Profits Double

After reporting a loss after tax last year, India’s Indoco has recovered and reported a substantial post-tax profit, as well as operating profit that doubled in its latest financial year, despite battling supply chain issues caused by the coronavirus crisis.

India Lifts Export Restrictions

India has removed export restrictions on APIs and formulations imposed by the country in March. However, certain measures have been kept in place to ensure that domestic requirements are met for in-demand products such as hydroxychloroquine and paracetamol.

Related Content

Topics

UsernamePublicRestriction

Register

GB149668

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel